Skip to main content
Fig. 1 | Diabetology & Metabolic Syndrome

Fig. 1

From: Evaluating the long-term cost-effectiveness of fixed-ratio combination insulin degludec/liraglutide (IDegLira) versus other treatment regimens in the chinese type 2 diabetes patients

Fig. 1

Breakdown of direct costs by cost category. Costs were categorized as treatment costs (costs associated with diabetes therapy), management costs (associated with routine care) and complication costs (associated with cardiovascular, renal, diabetic foot or neuropathy, or ocular complications)

Back to article page

Diabetology & Metabolic Syndrome

ISSN: 1758-5996

Contact us